Discover how a newly developed platform technology from The University of North Carolina at Chapel Hill can enhance RNAi ...

How do immune cells strike a balance, unleashing rapid attacks against pathogens or cancer, while avoiding damage to healthy ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., by brothers David and Tom ...

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...

Good day, and thank you for standing by. Welcome to the Moderna's Third Quarter 2025 Conference Call. [Operator Instructions] Please be advised today's conference is being recorded. I would now like ...

Moderna, Inc (NASDAQ:MRNA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below. Good day and thank you for ...

N6-methyladenosine (m6A) is the most prevalent internal modification of eukaryotic mRNA and has emerged as a pivotal regulator of gene expression at the post-transcriptional level. In the tumor immune ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, ...

Marissa Russo is a former STAT intern supported by the AAAS Mass Media Science & Engineering Fellowship. In a sign of the mRNA field’s recent dynamism, the Alliance for mRNA Medicines doubled its size ...

Many public health experts and scientists say they are stunned by Health Secretary Robert F. Kennedy Jr’s decision to cancel nearly half a billion dollars in federal funding for future vaccine ...